Ofranergene obadenovec

Drug Profile

Ofranergene obadenovec

Alternative Names: GT-111; VB 111

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vascular Biogenics
  • Developer Dana-Farber Cancer Institute; Massachusetts General Hospital; VBL Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Angiogenesis modulating agents; Gene expression modulators; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Ovarian cancer; Thyroid cancer
  • Preclinical Lung cancer; Malignant melanoma

Most Recent Events

  • 19 Jun 2017 Efficacy data from a phase II trial in Thyroid cancer released by VBL Therapeutics
  • 19 Jun 2017 Updated efficacy data from a phase II trial in Ovarian cancer released by VBL Therapeutics
  • 05 Jun 2017 Additional efficacy data from a phase II trial in Glioblastoma released by VBL Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top